Advertisement
Kezar Life Sciences, Inc. (KZR)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
| Previous Close | 7.62 |
| Open | 7.50 |
| Bid | 7.47 x 200 |
| Ask | 7.57 x 100 |
| Day's Range | 7.41 - 7.60 |
| 52 Week Range | 5.20 - 11.40 |
| Volume | |
| Avg. Volume | 97,942 |
| Market Cap | 54.722M |
| Beta (5Y Monthly) | 0.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -13.12 |
| Earnings Date | Nov 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.50 |
Clinical Trials ArenaKezar struck again with second FDA hold
Kezar dropped the programme investigating zetomipzomib in lupus after the first hold in October.
Business WireKezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., November 12, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.